Ibuprofen three times

Phase 2Small molecule

NNaval Health Research Center

Ibuprofen three times is one of 7 small molecule programs targeting Altitude Sickness. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Altitude SicknessActive, not recruiting

Altitude SicknessPhase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Altitude Sickness

#DrugCompanyPhaseTrials

Letairis

Gilead

Approved

—2

Truphylline

TThe Searle Company Limited Pakistan

Approved

—3

Acetadote

AArbor Pharmaceuticals, Inc.

Diamox

2 5

Pulmicort

SSalix

Phase 3

1 6

Advil

KKenvue Brands

Phase 1

1 7

Ibuprofen three times

NNaval Health Research Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Altitude Sickness1 trial

NSAID RCT for Prevention of Altitude Sickness

Unknown status·NNaval Health Research Center·Phase 2·NCT01606527·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ibuprofen three times. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ibuprofen three times compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ibuprofen three times. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Naval Health Research Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNaval Health Research Center

Ibuprofen three times

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Altitude Sickness1 trial

References

Drug Info

Quick Facts

Related News